Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 442-446

  Kuo, Dennis Yi Shin ^a   Blank, Stephanie V ^b   Christos, Paul J ^c   Kim, Mimi ^a   Caputo, Thomas A ^c   Pothuri, Bhavana ^b   Hershman, Dawn ^d   Goldman, Noah ^e   Ivy, Percy S ^f   Runowicz, Carolyn D ^g   Muggia, Franco ^b   Goldberg, Gary L ^a   Einstein, Mark H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f CTEP   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Oxaliplatin; Paclitaxel; Recurrent cervical cancer; Response; Toxicity

Indexed keywords

OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INTESTINE FISTULA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MENTAL DEFICIENCY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SAMPLE SIZE; SOMNOLENCE; SURVIVAL RATE; THERAPY DELAY; THERAPY EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VAGINA BLEEDING; VOMITING; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 75749123491     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.082     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 59 (2009) 225-273 2009
2. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153
3. Omura G.A. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J. Natl. Cancer Inst. Monogr. (1996) 123-126
4. Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 22 (2004) 3113-3119
5. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23 (2005) 4626-4633
6. Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H., et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 27 28 (2009) 4649-4655
7. Culy C.R., Clemett D., and Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60 (2000) 895-924
8. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br. J. Cancer 77 Suppl 4 (1998) 8-11
9. Thuss-Patience P.C., von Minckwitz G., Kretzschmar A., Loibl S., Schaller G., Dorken B., et al. Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 14 (2003) 549-553
10. Cortinovis D., Bidoli P., Zilembo N., Fusi A., and Bajetta E. Oxaliplatin doublets in non-small cell lung cancer: a literature review. Lung Cancer 60 (2008) 325-331
11. Tomek S., and Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 45 Suppl 1 (2004) S103-S119
12. Machover D., Delmas-Marsalet B., Misra S.C., Gumus Y., Goldschmidt E., Schilf A., et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann. Oncol. 12 (2001) 1439-1443
13. Faivre S., Kalla S., Cvitkovic E., Bourdon O., Hauteville D., Dourte L.M., et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann. Oncol. 10 (1999) 1125-1128
14. Winegarden J.D., Mauer A.M., Otterson G.A., Rudin C.M., Villalona-Calero M.A., Lanzotti V.J., et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann. Oncol. 15 (2004) 915-920
15. NCCN Clinical Practice Guidelines. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. accessioned 7/6/09.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10 (1989) 1-10
18. D.Y.S. Kuo, B. Kobrinsky, P. Christos, S. Blank, T. Caputo, C.D. Runowicz et al., Oxaliplatin plus paclitaxel in first-line for recurrent and metastatic cervical cancer. J. Clin. Oncol., ASCO Annual Meeting Proceedings Part I. 2007;25, No. 18S (June 20 Supplement): 5549.
19. NCI Alert for the use of concomitant chemoradiotherapy. In; http://www.cancer.gov/newscenter/cervicalcancer. Accessioned 7/6/09.
20. Stordal B., Pavlakis N., and Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev. 33 8 (2007) 688-703
21. Long III H.J. Discussion of abstract # 27: Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecol. Oncol. 112 2 (2009) S15